Therapy for diffuse large B-cell lymphoma: getting personal

Affiliations

Comment

Bruce D Cheson. Lancet. 2013.

. 2013 May 25;381(9880):1793-4.

doi: 10.1016/S0140-6736(13)60849-1. Epub 2013 Apr 22.

¹ Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA. bdc4@georgetown.edu

No abstract available

Comment on

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D. Cunningham D, et al. Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22. Lancet. 2013. PMID: 23615461 Clinical Trial.

Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
Wang D, Liu P, Zhang Y, Liu HY, Shen D, Che YQ. Wang D, et al. Biomed Res Int. 2018 Nov 11;2018:1042597. doi: 10.1155/2018/1042597. eCollection 2018. Biomed Res Int. 2018. PMID: 30534553 Free PMC article.
Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.
Carbone A, Gloghini A, Kwong YL, Younes A. Carbone A, et al. Ann Hematol. 2014 Aug;93(8):1263-77. doi: 10.1007/s00277-014-2116-y. Epub 2014 May 29. Ann Hematol. 2014. PMID: 24870942 Free PMC article. Review.